Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Effect of the Combination of Umeclidinium and Vilanterol on Exercise Endurance Time in Subjects With COPD
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Jul 2023
Price :
$35
*
At a glance
- Drugs Umeclidinium/vilanterol (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 27 Jun 2018 Results of a pooled post-hoc analysis from ten studies published in the Drugs and Aging.
- 16 Jun 2016 Status changed from active, no longer recruiting to completed.
- 19 Nov 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.